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Ramalho, 59, 7000-671 Évora, Portugal
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ABSTRACT: New ruthenium methyl-cyclopentadienyl com-
pounds bearing bipyridine derivatives with the general formula
[Ru(η5-MeCp)(PPh3)(4,4′-R-2,2′-bpy)]+ (Ru1, R = H; Ru2,
R = CH3; and Ru3, R = CH2OH) have been synthesized and
characterized by spectroscopic and analytical techniques. Ru1
crystallized in the monoclinic P21/c, Ru2 in the triclinic P1̅,
and Ru3 in the monoclinic P21/n space group. In all molecular
structures, the ruthenium center adopts a “piano stool”
distribution. Density functional theory calculations were
performed for all complexes, and the results support
spectroscopic data. Ru1 and Ru3 were poor substrates of
the main multidrug resistance human pumps, ABCB1,
ABCG2, ABCC1, and ABCC2, while Ru2 displayed inhibitory
properties of ABCC1 and ABCC2 pumps. Importantly, all compounds displayed a very high cytotoxic profile for ovarian cancer
cells (sensitive and resistant) that was much more pronounced than that observed with cisplatin, making them very promising
anticancer agents.
■ INTRODUCTION
The increasing research in the area of metallodrugs has
positioned ruthenium complexes as promising drugs for cancer
therapy, particularly because of the progression through clinical
trials of some inorganic ruthenium(III) complexes, namely
NAMI-A, [ImH][trans-RuCl4(DMSO) Im] (Im = imidazole),
and KP1019, [Hind][trans-RuCl4(ind)2] (ind = indazole).
1−3
In addition, the growing research on ruthenium organometallic
chemistry unveiled important features for the metallodrug field
such as the lower toxicity of ruthenium drugs relative to
platinum-based drugs (e.g., cisplatin, CDDP) and different cell
targets than DNA.4−6 Thus, different modes of action are
possible, resulting in a better efficiency and less toxic side
effects than those of the metallodrugs in clinical use.
Our research group has focused on the search for new Ru(II)
and Fe(II) “piano stool” cationic complexes as anticancer
agents. In this frame, diverse sets of complexes of the general
formula [MII(η5-C5H5)(PP)(L)]
+ were designed and synthe-
sized, with MII = Ru, Fe; PP = monodentate or bidentate
Received: February 9, 2018
Published: April 3, 2018
Article
pubs.acs.org/ICCite This: Inorg. Chem. 2018, 57, 4629−4639
© 2018 American Chemical Society 4629 DOI: 10.1021/acs.inorgchem.8b00358
Inorg. Chem. 2018, 57, 4629−4639
phosphane; and L = N-monodentate or N,N′/N,O bidentate
heteroaromatic ligands. Most of these compounds present
cytotoxic activities in the nano- and submicromolar range on
several human cancer cell lines (e.g., MiaPaCa, LoVo, PC3, HL-
60, MCF7, HT29, A2780/A2780cisR, HeLa, MDAMB231,
among others) with IC50 values generally lower than those of
cisplatin, placing them among the best cytotoxic Ru(II) and
Fe(II) organometallic complexes.7−20
Adequate substitutions on the coordinated phosphane and
heteroaromatic ligands influence the electronic properties of
these complexes, their biological interaction, and ultimately
their mode of action.5 The hydrophilicity−lipophilicity balance
can also be controlled by introduction of adequate functional
groups in the coordinated ligands.15 The cationic nature of
these complexes also allowed the exploitation of different
counteranions that were revealed to influence the overall
cytotoxicity of the compounds as well.5 Globally, our studies
showed that N,N′ and N,O heterocyclic bidentate molecules
are the most suitable ligands, together with triphenylphosphane
as coligand, and the triflate anion the favored counterion.
The important role of the cyclopentadienyl ligand on the
stabilization of the ruthenium(II) center for this structural
piano stool arrangement was revealed by electrospray ionization
mass spectrometry studies.21 Indeed, the fragmentation path-
ways and energetics of a series of [RuCp(PPh3)(N,N′)]-
[CF3SO3] compounds always showed the “RuCp” entity at the
end of the fragmentation chain, even at high values of energy.21
Although the mechanism of action for these complexes is still
not completely understood, inductively coupled plasma mass
spectrometry results concerning the ruthenium distribution
within the several cellular compartments indicate that the
interaction with the cell membrane will determinate their
mechanism of action.15,22
Our continuing studies on the systematic substitutions on
the coordinated ligands in the half-sandwich structured
compounds based on the “RuCp” scaffold lead us to the recent
synthesis of a novel ruthenium methyl-cyclopentadienyl
complex, “RuMeCp”, bearing a bipyridine perfluorinated ligand
(perFluor-bpy).23 The strong activity of [Ru(η5-MeCp)(PPh3)-
(perFluor-bpy)][CF3SO3] toward colorectal cancer cells
stimulated the pursuit of these studies.
Although the chemistry of “MeCpRu(II)”-based compounds
is quite extensive,24−29 mainly fuelled by their catalytic
properties, the literature is scarce in what concerns mono-
nuclear compounds derived from MeCpRu(II)-containing
nitrogen coordinated heteroaromatic ligands. As far as we
know, only recently has another compound been reported that
presents a nitrogen bidentate ligand, namely [Ru(η5-MeCp)-
(tBu2-im)(NCMe)][PF6],
30 which was prepared from [Ru(η5-
MeCp)(NCMe)3][PF6].
26
The work presented here constitutes a new approach for the
synthesis of complexes presenting the general formula [Ru(η5-
MeCp)(PPh3)(N,N)]
+ using [Ru(η5-MeCp)(PPh3)Cl] as a
starting material.23
The poor efficacy of cancer chemotherapy often occurs as a
result of the intrinsic or acquired resistance to a large range of
chemotherapeutic agents, a phenotype called multidrug
resistance (MDR). Overexpression of ATP-binding cassette
(ABC) cell-membrane transporters has been shown to be
responsible for MDR, resulting mostly in an increased drug
efflux. The identification of selective inhibitors that block such a
mechanism efflux is then pertinent to be explored.31 With this
aim, the biological studies were focused on the evaluation of
compounds’ ability to inhibit the most critical proteins involved
in MDR belonging to the ABC family, the P-glycoprotein (P-
gp, ABCB1), the multidrug resistance proteins 1 and 2 (MRP1
and MRP2, ABCC1 and ABCC2) and the breast cancer
resistance protein (BCRP, ABCG2).
■ RESULTS AND DISCUSSION
Synthesis. A new family of ruthenium−methylcyclopenta-
dienyl complexes incorporating bipyridyl derivatives was
isolated as triflate salts for the first time. The complex
[Ru(η5-MeCp)(PPh3)2Cl], recently reported by us,
23 showed
to be an adequate starting material to perform the synthesis of a
new series of mono cationic ruthenium(II) complexes with
general formula [Ru(η5-MeCp)(PPh3)(4,4′-R-2,2′-bpy)]+
(Ru1, R = H; Ru2, R = CH3; Ru3, R = CH2OH). Sigma
coordination of the bidentate N,N′ chelating ligands to the
ruthenium core was achieved in good yields by halide
abstraction from the starting material [Ru(η5-MeCp)-
(PPh3)2Cl] with silver triflate (AgCF3SO3), as presented in
Scheme 1. Purification of the organometallic complexes was
achieved by slow diffusion recrystallization, at room temper-
ature, affording for all three compounds adequate crystals for
single-crystal X-ray diffraction studies.
The formulation and purity of the new family of complexes
(Ru1, Ru2, and Ru3) is supported by Fourier transfrom
infrared (FTIR); ultraviolet−visible (UV−vis); and 1H, 13C,
and 31P NMR spectroscopic data. Elemental analyses and
single-crystal X-ray diffraction corroborated their structures.
NMR Spectroscopy. Table S1 summarizes the 1H NMR
data for the new compounds. All resonances were attributed
using 1D and 2D NMR experiments [1H, 13C, correlation
spectroscopy (COSY), heteronuclear multiple quantum coher-
ence (HMQC), and heteronuclear multiple bond coherence
(HMBC)] and follow the atom numbering presented in
Scheme 1. Synthetic Route of the New Ru(II) Complexesa
aCompounds are numbered for NMR assignments.
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Scheme 1. Ru1−Ru3 showed three different resonances in their
1H NMR spectra that were ascribed to the three nonequivalent
protons of the methyl-cyclopentadienyl unit. These resonances
appeared as a doublet at ∼1.65 ppm for the methyl group and
as a broad singlet or a multiplet in the range 4.57−4.74 ppm for
the two remaining protons of the ring. The splitting detected
for the peaks at ∼1.65 and ∼4.60 ppm can be addressed to the
long-range coupling (4JHH) between the protons H1 and H3. In
this case, a favorable geometry alignment along the H−C−C−
C−H π chain (mimicking an allylic system) could be obtained
and, in all cases, observed with small long-range coupling
constants (4JH1−H3 ∼ 1.6 Hz).
32 The evident deshielding on the
H5 protons, adjacent to the nitrogen of the bipyridine ring, and
a shielding on the H8 protons ligand, observed in all complexes,
are clear evidence of successful coordination of the bipyridyl
derivative to the metal. Additionally, three resonances appeared
as triplet signals (7.41 ppm < δ < 7.10 ppm) in all 1H NMR
complexes’ spectra, which were readily attributed to the
aromatic protons of the triphenylphosphane coligand.
Characterization of these complexes was completed with
APT-13C{1H} NMR measurements. The results are in
accordance with the previously discussed effects in the 1H
NMR analysis. All the detailed spectroscopic data concerning
the 13C NMR experiments are in the Experimental Section. The
31P NMR spectra showed a unique sharp singlet resonance at
∼δ 51.8 ppm that was easily attributed to the coordinated
triphenylphosphane coligand for the three compounds and is in
good agreement with all 1H NMR and 13C NMR collected data.
FTIR Spectroscopy. The analysis of the solid-state FTIR
spectra of the organometallic ruthenium methyl-cyclopenta-
dienyl derivatives Ru1−Ru3 shows the presence of the typical
bands expected for the respective νCH stretching of the aromatic
rings of methylcyclopentadienyl, bipyridyl, and phosphane
ligands in the range 3080−3000 cm−1 and ∼2900 cm−1 for the
methyl group. Also, the expected bands for CC at 1400−
1600 cm−1, together with C−C and C−H bonding at
approximately 1030 and 1380 cm−1, respectively, were
observed. The presence of the triflate counterion was revealed
in the typical region for this group (ca. 1260 cm−1), which
agrees with the cationic character of the compounds. The
hydroxyl groups of the bpy(CH2OH)2 were also found at 3421
cm−1 for complex Ru3.
UV−Vis Spectroscopy. The optical absorption spectra of
all ruthenium-cyclopentadienyl complexes were recorded using
1.0 × 10−4 to 1.0 × 10−5 M solutions in dichloromethane and
dimethyl sulfoxide. Table S2 presents the values obtained for
the molar absorptivity coefficient (ε) and the corresponding
wavelength (λmax), whereas Figure 1 shows the spectrum of
compound Ru3, which typifies the general behavior of these
compounds. The strong absorption band observed at higher
energy, ∼290 nm is commonly attributed to the π−π*
transitions occurring in aromatic ligands. Our density functional
theory (DFT) studies (see below) revealed that this intense UV
band is mainly an interligand transition involving an electron
transfer from a π orbital based on the phosphane and on the η5-
MeCp ligands to the π* orbital centered at the bpy coordinated
molecules with some contribution of the Ru. A second band
observed in all the spectra, occurring in the range of 336−386
nm can be considered a metal-to-ligand charge-transfer
(MLCT) band because it involves a π bonding orbital mainly
centered on Ru to a π* orbital centered on a bpy-R ligand. The
band occurring in the visible part of the spectra, in the range of
420−450 nm, with ε values from 3.3 to 6.8 × 103 M−1 cm−1,
depending on the solvent, corresponds also to charge-transfer
transitions from the Ru to both PPh3 and bpy-R ligands. For
details, see Table 3 in DFT Studies.
Electrochemical Studies. The electrochemical behavior of
these new organometallic ruthenium methyl-cyclopentadienyl-
based complexes was studied at room temperature by cyclic
voltammetry in acetonitrile and dichloromethane solutions.
Table 1 summarizes the electrochemical data for complexes
bearing bipyridyl derivatives. Figure 2 shows the behavior of
complex Ru2 in acetonitrile.
All the compounds present the typical electrochemical
behavior observed for other ruthenium similar compounds,
displaying one-electron quasi-reversible coupled redox process
in both solvents in the positive potentials range. In acetonitrile,
these quasi-reversible processes at E1/2 = 0.92, 0.91, and 0.89 V,
for Ru1, Ru2, and Ru3, respectively, can be attributed to the
RuII/RuIII redox couple, in accordance with our earlier results
for some ruthenium-cyclopentadienyl analogous.9,15−17 At
negative potentials, a quasi-reversible redox process (E1/2
between −1.50 and −1.61 V) was also observed for all the
complexes, which can be attributed to a bipyridyl ligand-based
process.
In dichloromethane, the complexes presented the same
general behavior concerning the RuII/RuIII redox couple with
quasi-reversible processes at E1/2 = 0.95, 0.92, and 0.90 V, for
Ru1, Ru2, and Ru3, respectively. These redox processes are
followed by one (Ru1) or two (Ru2 and Ru3) irreversible
waves probably attributed to ligand-centered oxidation
processes, as was also found for related complexes.9,17 The
ligand-based redox process found in the negative potentials
range in acetonitrile is not observed in dichloromethane.
Concerning the complexes Ru1 and Ru2, the redox
potentials found for the RuII/RuIII redox pair are slightly
lower than the ones found for the related complexes [Ru(η5-
C5H5)(PPh3)(bpy)][CF3SO3] and [Ru(η
5-C5H5)(PPh3)-
(Me2bpy)][CF3SO3] (E1/2 = 1.05 and 0.96 V in dichloro-
methane, respectively)9,17 in the same experimental conditions.
This observation is in accordance with the higher electronic
density in the cationic ruthenium(II) center due to the
introduction of the electron donor methyl group in the
cyclopentadienyl ring. The comparison between the RuII/RuIII
redox potentials for the three complexes Ru1−Ru3 in both
solvents showed that the presence of different substituents on
the p-position of the bipyridine rings has some influence on the
electronic environment of the ruthenium(II) center, making
easier the oxidation process. Moreover, the tendency observed
Figure 1. Electronic spectra of complex Ru3 in dichloromethane
(solid line) and dimethyl sulfoxide (dashed line) showing the
expansion in the range of the CT band.
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follows the order Ru3 > Ru2 > Ru1 and is in agreement with
the highest occupied molecular orbital (HOMO) relative
energies (calculated by DFT).
Single-Crystal Structures of [Ru(η5-MeCp)(PPh3)(bpy-
R)][CF3SO3] Complexes Ru1−Ru3. Ru1, Ru2, and Ru3
crystallize from dichloromethane/n-hexane (Ru1 and Ru2) or
dichloromethane/diethyl ether (Ru3) solutions as red blocks
(crystal dimensions 0.43 × 0.15 × 0.09 mm for Ru1, 0.28 ×
0.17 × 0.08 mm for Ru2, and 0.27 × 0.25 × 0.14 mm for Ru3).
Figure 3 shows ORTEP representations of Ru1, Ru2, and Ru3.
In Ru2, the asymmetric unit contains two ruthenium cation
complexes, two (CF3SO3)
− anions, and two CH2Cl2 molecules,
which are not in symmetric positions with respect to the
inversion center of the space group. In the other two
compounds, only one ruthenium cation complex and
(CF3SO3)
− anion are present in the asymmetric unit.
In the three molecular structures, the ruthenium center
adopts a “piano stool” distribution formed by the ruthenium-
MeCp unit bound to one PPh3 and one bpy ligand. The
distances for Ru−P bonds are in the range of 2.305−2.315 Å,
and the distances for Ru−N bonds are in the range of 2.077−
2.092 Å (Table S3). The distances between Ru and the
centroids of the π-bonded cyclopentadienyl moiety are
1.8340(9) Å in Ru1, 1.8317(13) Å and 1.8346(13) Å for the
two complexes present in the asymmetric unit in Ru2, and
1.8284(10) Å in Ru3 to Ru centers (ring slippage 0.046 Å in
Ru1, 0.049 and 0.057 Å in Ru2, and 0.044 Å in Ru3). The
mean value of the Ru−C bond distance is 2.198(2) Å for Ru1,
2.196(2) Å for Ru2 [only for Ru(1) metal center], and
2.194(2) Å for Ru3. The Ru−C distances are longer in the
carbon atoms around the methyl group, in the range of 2.20−
2.23 Å, as in other examples of Cp substitution found in the
literature.33 Table S3 contains selected bond lengths and angles
for the three compounds.
X-ray structure analysis of the structures shows two




+ in the racemic crystals, the
chirality being due to a twist of the PPh3 and Cp units. The
Table 1. Electrochemical Data for Complexes Ru1−Ru3a
acetonitrile dichloromethane
compound Epa (V) Epc (V) E1/2 (V) Epa − Epc (mV) Ic/Ia Epa (V) Epc (V) E1/2 (V) Epa − Epc (mV) Ic/Ia
Ru1 − − − − − 1.49 − − − −
0.96 0.88 0.92 80 1.0 0.99 0.90 0.95 90 0.6
−1.55 −1.61 −1.58 60 0.5b − − − − −
Ru2 − − − − − 1.62 − − − −
− − − − − 1.40 − − − −
0.95 0.87 0.91 80 0.9 0.96 0.88 0.92 80 0.8
−1.58 −1.65 −1.61 70 1.0b − − − − −
Ru3 − − − − − 1.63 − − − −
− − − − − 1.36 − − − −
0.93 0.84 0.89 90 0.9 0.94 0.86 0.90 80 0.9
−1.46 −1.55 −1.51 90 0.4b − − − − −
aAll values vs SCE; v = 100 mV·s−1. bIa/Ic.
Figure 2. Cyclic voltammogram of Ru2 in acetonitrile (scan rate = 100
mV·s−1).
Figure 3. ORTEP for the cation complex in the compounds (A) [Ru(η5-MeCp)(PPh3)(bpy)][CF3SO3] (Ru1), (B) [Ru(η
5-MeCp)(PPh3)-
(Me2bpy)][CF3SO3] (Ru2), and (C) [Ru(η
5-MeCp)(PPh3)(bpy(CH2OH)2))][CF3SO3] (Ru3). All the non-hydrogen atoms are presented by their
50% probability ellipsoids. Hydrogen atoms are omitted for clarity.
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cation complexes present a mirror plane which contains P, Ru,
and the centroid of Cp rings (Figure S1).18,34 Intermolecular
hydrogen bonds are present in Ru3, between the hydroxyl
groups and oxygen atoms of (CF3SO3)
− anions (Table 2).
DFT Studies. To support our spectroscopic data, DFT
calculations were performed for all complexes. The optimized
structures are shown in Figure S2, and the relevant structural
parameters are shown in Table S4. The calculated bond lengths
and angles are consistent with crystallographic data. For
instance, calculated X−C (X = C, N, and Ru), Ru−N, and
Ru−P bond lengths show differences up to only +0.01, +0.05,
and +0.15 Å, respectively, relative to those obtained from X-ray
crystal structures. Also, small deviations of the calculated angles,
up to 2°, were found.
Donor−acceptor interactions between bpy (or PPh3) and
[Ru(η5-MeCp)(PPh3)]
+ (or [Ru(η5-MeCp)(bpy)]+) fragments
were assessed by charge decomposition analysis (CDA)35 and
are also shown in Table S4. As expected, it can be seen that L′
→ [Ru(η5-MeCp)(L)]+ σ-donation is always greater than
[Ru(η5-MeCp)(L)]+ → L′ π-backdonation for all complexes.
The relative weights of the two donor−acceptor components,
expressed in terms of the percent of its contribution to the
overall interaction, show that the contribution of [Ru(η5-
MeCp)(PPh3)]
+ → bpy π-backdonation interaction is only
moderate (20−26%). After the geometry optimizations, the
electronic spectra were simulated by means of time-dependent
density functional theory (TD-DFT) calculations with the
inclusion of solvation effects. Table 3 shows the main vertical
optical transitions that contribute to the overall calculated
spectra. Experimental data are also included for comparison. As
an example, the calculated spectrum of complex Ru3 and its
experimental spectrum in dichloromethane are depicted in
Figure 4.
Our TD-DFT results predict an intense UV band, together
with several low intensity bands in the visible region, in
accordance with experimental spectra. The overall agreement
between the theoretical and experimental spectra is very good.
For example, only small deviations (up to 8 nm) between
calculated and experimental λmax were found. Representations
of the main orbitals contributing to these excitations are
depicted in Figure S3. On the basis of the TD-DFT
calculations, the experimental intense UV band, in the range
λ = 288−292 nm, can be attributed mainly to interligand
transitions with some contribution of Ru to π*, in particular for
Ru1. The experimental band at λ = 332−336 nm, attributed a
π(Ru+η5-MeCp)−π*(bpy+phosphane) transition, can be
viewed as a typical MLCT (L = bpy). The experimental band
at λ = 423−428 nm is predicted to be a result of a combination
of two vertical excitations closer in energy. A π bonding orbital
mainly centered on Ru is involved. However, the character of
Table 2. Hydrogen Bonds in the Compound [Ru(η5-MeCp)(PPh3)(bpy(CH2OH)2))] [CF3SO3] (Ru3)
D−H···A d(D-H) d(H···A) d(D···A) (DHA)
O(1)-H(1O)···O(3)a 0.84(3) Å 1.92(3) Å 2.751(2) Å 168(3)°
O(2)-H(2O)···O(5)b 0.77(3) Å 2.02(3) Å 2.787(3) Å 177(3)°
aSymmetry transformations used to generate equivalent atoms: 1 − x + 3/2, y + 1/2, −z + 3/2. bSymmetry transformations used to generate
equivalent atoms: x, y + 1, z.







(nm)b major contributions (%)c attributiond
Ru1 − 512 512 (0.0002) H → L(90) Ru(80), η5-MeCp(15), PPh3(5) → bpy(100)
488 (sh) 484 484 (0.0328) H−1 → L(74), H−2 → L(16) Ru(76), η5-MeCp(16), PPh3(8) → bpy(100)
428 (3.3) 428 432 (0.0363) H−2 → L(48) Ru(57), η5-MeCp(42), PPh3(1) → bpy(100)
416 (0.0339) H−1 → L+3(47) Ru(83), η5-MeCp(17) → PPh3(70), bpy(30)
− 363 363 (0.0219) H−1 → L+1(89) Ru(78), η5-MeCp(21), PPh3(1) → bpy(100)
333 (5.5) 332 332 (0.0343) H−2 → L+1(84) Ru(84), η5-MeCp(16) → bpy(93), PPh3(7)
291 (21.4) 287 287 (0.1463) H−4 → L(28), H−1 → L+7(19), H−1 → L+9(26) η5-MeCp(74), bpy(14), PPh3(12) → Ru(100)
286 (0.2314) H−4 → L(39), H−1 → L+7(11), H−1 → L+9(15) η5-MeCp(79), PPh3(21) → Ru(89), bpy(11)
Ru2 − 502 502 (0.0007) H → L(90) Ru(80), η5-MeCp(15), PPh3(5) → bpy(100)
478 (sh) 475 475 (0.0426) H−1 → L(78), H−2 → L(12) Ru(74), η5-MeCp(16), PPh3(10) → bpy(100)
423 (4.6) 424 425 (0.0324) H−2 → L(67) Ru(86), η5-MeCp(14) → bpy(97), PPh3(3)
420 (0.0288) H−1 → L+2(44) Ru(80), η5-MeCp(20) → PPh3(81), bpy(19)
− 360 360 (0.0264) H−1 → L+1(85) Ru(70), η5-MeCp(27), PPh3(13) → bpy(100)
336 (5.6) 328 328 (0.0371) H−2 → L+1(69), H → L+4(10) Ru(80), η5-MeCp(20) → bpy(77), PPh3(23)
288 (24.8) 286 286 (0.3098) H−4 → L(66) PPh3(64), η5-MeCp(36) → bpy(93), Ru(7)
Ru3 − 512 512 (0.0007) H → L(97) Ru(80), η5-MeCp(15), PPh3(5) → bpy(100)
472 (sh) 480 480 (0.0398) H−1→L(83), H−2 → L(14) Ru(84), η5-MeCp(17), PPh3(9) → bpy(100)
424 (3.6) 428 430 (0.0630) H−2 → L(76), H−1 → L(11) Ru(83), η5-MeCp(15), PPh3(2) → bpy(100)
417 (0.0310) H−1 → L+2(45) Ru(73), η5-MeCp(27) → PPh3(82), bpy(18)
354 (sh) 353 353 (0.0268) H−1 → L+1(87) Ru(63), η5-MeCp(34), PPh3(3) → bpy(100)
332 (sh) 324 324 (0.0320) H−2 → L+1(74) Ru(73), η5-MeCp(27) → bpy(87), PPh3(13)
292 (20.8) 287 287 (0.4134) H−4 → L(72) PPh3(67), η5-MeCp(33) → bpy(83), Ru(17)
aMaxima of the convoluted bands (exptl.: ε × 103 M−1 cm−1). bOscillator strength, f, in a.u. in parentheses. cH = HOMO, L = LUMO. dBased on
the represented fragments (overall percent of the charge transfer in parentheses).
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.8b00358
Inorg. Chem. 2018, 57, 4629−4639
4633
π* is different: one is clearly centered on the bpy ligand (thus
originating a MLCT similar to the one observed for λ = 332−
336 nm), and the other is mainly centered on phosphane. The
corresponding electron density difference maps (EDDMs)
illustrate this behavior (Figure 5).
Stability Studies in Aqueous Media. Stability in a
physiological like media prior to in vitro evaluation of
metallodrugs is a very important issue when assessing the
mettallodrugs’ biological activity.36 In this context, all
complexes were tested for their aqueous stability over time
using DMSO and culture cellular media DMEM by UV−vis
spectroscopy. DMSO was used to dissolve the compounds
because they are not completely soluble in the DMEM media.
The samples used in the measurements were protected from
light sources and were stored at room temperature between
measurements. Only small variations (lower than 6% over 24 h)
were observed for all complexes with the bipyridyl derivatives,
indicating that the complexes are quite stable over the period
tested (Figure S4). Taken together, these results indicate that
the compounds are stable in these conditions and the original
solid-state three-legged piano stool molecular architecture,
bearing the bipyridyl and the phosphane coligands, is kept as
such in solution during this period.
Biological Evaluation of the Ru Compounds. We first
aimed at evaluating the cytotoxicity of the Ru compounds and
their behavior toward ABC pumps. Indeed, one major
limitation in chemotherapy is the acquired resistance that
cancer cells can develop because of the action of MDR ABC
efflux transporters that reduce the anticancer drugs’ concen-
tration below their threshold of action.37 In this regard, the P-
gp, MRP1, MRP2, and BCRP (ABCB1, ABCC1, ABCC2, and
ABCG2 in terms of the HUGO nomenclature) are the most
studied pumps. Figure 6 presents the cytotoxic activity of the
complexes Ru1−Ru3 for the NIH3T3 and HEK293 control
cells and the same overexpressing of P-gp, MRP1, MRP2, or
BCRP.
As shown, the cytotoxicity varied with the compounds and
slightly with cells, as NIH3T3 cells were more sensible to the
Ru compounds than HEK293 cells. When the cells expressed
the MDR pumps, Ru2 exhibited equal toxicity, indicating that it
is not a substrate of these efflux pumps. In contrast, Ru1 was
found to be equally toxic for HEK293 cells regardless of the
presence or absence of the pumps, while notably, the
expression of P-gp in NIH3T3 cells conferred a 24× resistance,
showing that it is substrate of that pump. Finally, Ru3 displayed
close cytotoxicity levels for the cell lines and was revealed to be
10 times less toxic for P-gp-expressing cell line and 2 times less
toxic for MRP1, MRP2, and BCRP-expressing cells, again
showing that it is a substrate of these pumps, although rather
poor in the case of the last three pumps.
Because Ru2 was not found to be a substrate of the MDR
ABC pumps, we aimed at verifying if it can block their efflux
activity. For doing that, we probed the intracellular
accumulation of known substrates of each MDR pump using
flow cytometry and compared the results to that of reference
inhibitors. Results are displayed in Figure 7. Ru2 displayed a
poor inhibition capacity of P-gp and BCRP, but in contrast, it
was rather efficient in blocking the efflux activity of MRP1 and
MRP2.
Uptake of Ru1−Ru3 Complexes in HEK293 WT and
HEK 293 BCRP Cell Lines. We then evaluated the uptake of
Ru compounds in cells. To do that, we quantified the Ru in
Ru1−Ru3 penetrating into HEK293 cells using a mass
cytometry approach. For this purpose, the flow cytometry
was coupled with a microplate reader and an autosampler. The
experiment was carried out on HEK293 cells, with or without
BCRP expression.
The compounds Ru1 and Ru2 had the highest cell
internalization (Figure 8), for both control and BCRP-
expressing cells.
Cytotoxicity in Cisplatin-Sensitive and Cisplatin-
Resistant Ovarian Cancer Cells. The cytotoxicity of the
Ru1−Ru3 complexes was studied by the MTT assay on the
Figure 4. Experimental (black solid line) and calculated (red dashed
line) spectra for complex Ru3 in dichloromethane. The intensity of the
calculated spectrum was normalized for a better illustration.
Figure 5. Electron density difference maps (EDDMs) of the vertical
transition at 430 nm (left) and 417 nm (right) for the complex Ru3.
Blue indicates a decrease, and red indicates an increase in electron
density; isovalue = 0.001.
Figure 6. In vitro cytotoxic activity of complexes Ru1−Ru3 in
HEK293 or NIH3T3 cell lines expressing or not expressing the ABC
MDR transporters. Cells were incubated with various Ru concen-
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epithelial ovarian cancer cells A2780 and its cisplatin-resistant
subclone A2780cisR. The A2780 cell line was established from
tumor tissue from an untreated patient, while the A2780CisR
cell line was developed by chronic exposure of the parent cell
line to increasing concentrations of cisplatin. Cells were
incubated with each compound in serial concentrations within
the range of 0.01−100 μM for 24 h. The dose−response curves
of cellular viability were obtained (Figure S5), and the IC50
values calculated for Ru1−Ru3 are presented in Figure 9 and
Table S5. Cisplatin (CDDP) was also introduced for
comparison.
As can be seen, Ru1−Ru3 compounds exhibited high
cytotoxicity against the ovarian cells tested, displaying
inhibition growths 5−35 times better than cisplatin in the
A2780 cells and 10−120 times better in the cisplatin-resistant
cells A2780cisR. Ru2 displayed the highest efficacy in both
cases, being 3−10 times more efficient than Ru3 or Ru1. This
higher efficiency may be due to the more pronounced
hydrophobic character of the methyl substituents in Ru2
versus the hydrogen atom or hydroxymethyl group for Ru1 and
Ru3, respectively. None of the free ligands [bpy, Me2bpy, or
bpy(CH2OH)2] displayed cytotoxicity against the tested cells
within the concentration range studied (IC50 > 100 μM).
When (indirectly) compared to previous compounds
synthesized in our group, namely, the compounds with general
formula [Ru(η5-C5H5)(4,4′-R-2,2′-bpy)(PPh3)]+, with R = H
[IC50 A2780 (72 h) = 0.14 ± 0.01 μM]
11 and R = −CH3 [IC50
A2780 (72 h) = 0.1 ± 0.01 μM],9 we can state that the new
analogues with the methyl group in the Cp ring have retained
the high cytotoxic activity even at shorter incubation times.
■ CONCLUSIONS
Three new ruthenium(II) compounds with the general formula
[Ru(η5-MeCp)(PPh3)(4,4′-R-2,2′-bpy)]+ (Ru1, R = H; Ru2, R
= CH3; Ru3, R = CH2OH) have been described here for the
first time. Spectroscopic data and DFT analysis showed that π-
backdonation from the bipyridine and phosphane ligands is
present, even if the σ-donation is always larger. The higher
electronic density in the cationic ruthenium(II) center due to
the introduction of the electron donor methyl group in the
cyclopentadienyl can be observed by the lower redox potential
found for the RuII/RuIII redox pair, comparatively to their
related complexes without the methyl group.9,17 The
substituent groups on the p-position of the bipyridine rings
also exert some influence on the ruthenium oxidation process
that is easier for Ru3 > Ru2 > Ru1, which is in agreement with
the HOMO relative energies calculated by DFT. The three
compounds crystallize in centrosymmetric space groups (Ru1
and Ru3 in the monoclinic P21/c and P21/n, respectively; Ru2
in the triclinic P1 ̅) as enantiomers.
All compounds presented adequate stability for the biological
assays. We first aimed at evaluating their cytotoxicity and
behavior toward ABC pumps, which are responsible for
acquired resistance to treatment, one of the major limitations
in chemotherapy. Although Ru1 and Ru3 are (poor) substrates
of MDR pumps, Ru2 is not a MDR substrate but, notably,
displays inhibitory properties for MRP1 and MRP2 pumps. In
addition, all the compounds of this series were shown to be
potential cytotoxic agents as they show a high cytotoxic profile
in the human ovarian cancer cells tested with IC50 values
surpassing up to 120 times the metallodrug cisplatin under the
same experimental conditions. Ru1−Ru3 are also more
cytotoxic than other Ru(II)-arene related compounds from
the literature.38−40
Further studies will be performed to evaluate the underlying
mechanisms of action for these promising chemotherapeutic
agents, in particular for Ru2 that combines the cytotoxic effect
with the ability to overcome MDR.
■ EXPERIMENTAL SECTION
General Procedures. All reactions and manipulations were
performed under nitrogen atmosphere using Schlenk techniques. All
solvents used were dried and freshly distilled under nitrogen prior to
use, using standard methods.41 1H, 13C, and 31P NMR spectra were
Figure 7. Effect of Ru2 on the intracellular accumulation of MDR
ABC pumps substrates. Ru2 was added at 20 μM to HEK293 (MRP1,
MRP2, and BCRP) or NIH3T3 (P-gp) control and MDR ABC pumps
expressing cell lines. The concentration used for substrates was 5 μM
mitoxantrone for BCRP, 0.5 μM rhodamine 123 for P-gp, or 0.2 μM
calcein AM for MRP1 and MRP2. Reference inhibitors were 1 μM
Ko143 for BCRP, 5 μM GF120918 for P-gp, 35 μM verapamil for
MRP1, and 25 μM cyclosporine A for MRP2.
Figure 8. Intracellular quantitation of Ru1−Ru3 compounds in
HEK293 cell lines by CyTOF.
Figure 9. Cytotoxicity of Ru compounds and CDDP to cisplatin-
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recorded on a Bruker Avance 400 spectrometer at probe temperature
using commercially available deuterated solvents. 1H and 13C chemical
shifts (s = singlet; d = duplet; t = triplet; q = quartet; m = multiplet;
comp = complex) are reported in parts per million (ppm) downfield
from internal standard Me4Si, and the
31P NMR spectra are reported
in ppm downfield from external standard, 85% H3PO4. Coupling
constants are reported in Hz. All assignments were attributed using
APT-13C{1H} or 13C{1H}, COSY, HMBC, and HMQC NMR
techniques. Infrared spectra were recorded on KBr pellets using a
Mattson Satellite FTIR spectrophotometer, and only relevant bands
are cited in the text. Electronic spectra were obtained at room
temperature on a Jasco V-560 spectrometer from solutions of 10−4−
10−6 M in quartz cuvettes (1 cm optical path). Elemental analyses
were performed at Laboratoŕio de Anaĺises, at Instituto Superior
Tećnico, using a Fisons Instruments EA1 108 system. Data acquisition,
integration, and handling were performed using a PC with the software
package EAGER-200 (Carlo Erba Instruments). [Ru(η5-MeCp)-
(PPh3)2Cl] starting material was obtained following a literature
protocol.23
Synthesis. To a stirred and degassed solution of [Ru(η5-
MeCp)(PPh3)2Cl] (0.250 g, 0.34 mmol) in dichloromethane (40
mL) was added AgCF3SO3 (0.096 g, 0.37 mmol). The resulting
mixture was stirred for 1 h at room temperature followed by the
addition of 4,4′-R-2,2′-bipyridine (0.37 mmol of 2,2′-bipyridine for
Ru1, 0.38 mmol of 4,4′-dimethyl-2,2′-bipyridine for Ru2, and 0.38
mmol of 4,4′-dihydroxymethyl-2,2′-bipyridine for Ru3). After 8 h in
reflux, the orange color turned red (Ru1) or dark orange (Ru2 and
Ru3). The reaction mixture was cooled to room temperature and
filtered, and the solvent was removed under vacuum. Crystals were
obtained after recrystallization from dichloromethane/n-hexane at
room temperature for Ru1 and Ru2. For Ru3, the residue was
recrystallized once from dichloromethane/n-hexane and once from
tetrahydrofuran/ n-hexane; dark orange crystals were obtained after
room-temperature recrystallization from dichloromethane/diethyl
ether.
[Ru(η5-MeCp)(PPh3)(bpy)][CF3SO3] (Ru1). Yield: 52%; red crystals.
1H NMR [(CD3)2CO, Me4Si, δ (ppm)]: 9.46 (d, 2H,
3JHH = 5.6, H5),
8.19 (d, 2H, 3JHH = 8.0, H8), 7.90 (t, 2H,
3JHH = 7.6, H7), 7.39 (m, 5H,
HpPPh3 + H6), 7.31 (t, 6H,
3JHH = 7.6, HmPPh3), 7.10 (t, 6H,
3JHH =
9.6, HoPPh3), 4.74 (s, 2H, H4), 4.64 (m, 2H,
4JHH = 1.6, H3), 1.65 (d,
3H, 4JHH = 1.6, H1).
13C NMR [(CD3)2CO, δ (ppm)]: 156.8 (
3JCP = 2,
C5), 156.7 (C9), 137.0 (C7), 133.9 (
2JCP = 11, CHoPPh3), 132.7 (
1JCP =
42, CqPPh3), 131.0 (
4JCP = 2, CHpPPh3), 129.5 (
3JPC = 10, CHmPPh3),
126.4 (C6), 124.1 (C8), 103.5 (C2), 77.1 (C3+C4), 11.7 (d, C1).
31P
NMR [(CD3)2CO, δ (ppm)]: 51.8 [s, PPh3]. FTIR [KBr, cm
−1]: 3055
cm−1 (υC−H, aromatic, MeCp), 2922−2855 cm−1 (υC−H, MeCp), 1435
cm−1 (υCC, phenyl rings, MeCp), 1273 cm−1 (υCF3SO3 counterion).
UV−vis [DMSO, λmax (nm) (ε × 103 M−1 cm−1)]: 293 (21.5), 355
(Sh), 424 (3.5), 477 (Sh). UV−vis [CH2Cl2, λmax (nm) (ε × 103
M−1 cm−1)]: 291 (21.4), 333 (5.5), 428 (3.3), 488 (Sh). Elemental
analysis. Calcd for C35H30F3N2O3PRuS·1/10 CH2Cl2: C, 55.8; H, 4.0;
N, 3.7; S, 4.2. Found: C, 55.7; H, 4.0; N, 3.7; S, 4.0.
[Ru(η5-MeCp)(PPh3)(Me2bpy)][CF3SO3] (Ru2). Yield: 67%; dark
orange crystals. 1H NMR [(CD3)2CO, Me4Si, δ (ppm)]: 9.24 (d, 2H,
3JHH = 6.0, H5), 8.04 (s, 2H, H8), 7.43 (t, 3H,
3JHH = 6.0, HpPPh3),
7.22 (d, 2H, 3JHH = 6.8, H6), 7.33 (t, 6H,
3JHH = 7.2, HmPPh3), 7.12 (t,
6H, 3JHH = 8.0, HoPPh3), 4.68 (s, 2H, H4), 4.57 (m, 2H,
4JHH = 1.6,
H3), 2.46 (s, 6H, H10), 1.65 (d, 3H,
4JHH = 1.6, H1). APT-
13C{1H}
NMR [(CD3)2CO, δ (ppm)]: 156.3 (C9), 155.9 (
3JCP = 1.7, C5), 149.2
(C7), 133.8 (
2JCP = 11, CHoPPh3), 133.0 (
1JCP = 40, CqPPh3), 130.8
(4JCP = 2, CHpPPh3), 129.3 (
3JCP = 10, CHmPPh3), 127.3 (C6), 124.6
(C8), 103.0 (C2), 76.5 (C4), 76.4 (C3), 20.8 (C10), 11.7 (d, C1).
31P
NMR [(CD3)2CO, δ (ppm)]: 51.8 [s, PPh3]. FTIR [KBr, cm
−1]:
3073−3055 cm−1 (υC−H, phenyl, MeCp), 2922 cm−1 (υC−H MeCp),
1440 (υCC, phenyl rings, MeCp), 1260 cm−1 (υCF3SO3 counterion).
UV−vis [DMSO, λmax (nm) (ε × 103/M−1 cm−1)]: 291 (26.7), 333
(Sh), 418 (4.8), 479 (Sh). UV−vis [CH2Cl2, λmax (nm) (ε × 103
M−1 cm−1)]: 288 (24.8), 336 (5.6), 423 (4.6), 478 (Sh). Elemental
analysis. Calcd for C37H34F3N2O3PRuS·
1/3CH2Cl2: C, 55.7; H, 4.2; N,
3.4; S, 4.2. Found: C, 55.5; H, 4.2; N, 3.4; S, 3.7.
[Ru(η5-MeCp)(PPh3)(bpy(CH2OH)2))][CF3SO3] (Ru3). Yield: 58%;
dark orange crystals. 1H NMR [(CD3)2CO, Me4Si, δ (ppm)]: 9.34 (d,
2H, 3JHH = 5.6, H5), 8.10 (s, 2H, H8), 7.40 (t, 3H,
3JHH = 6.8, HpPPh3),
7.36 (d, 2H, 3JHH = 6.0, H6), 7.31(t, 6H,
3JHH = 7.2, HmPPh3), 7.11 (t,
6H, 3JHH = 8.8, HoPPh3), 4.79 (m, 4H, H10), 4.71 (s, 2H, H4), 4.60 (m,
2H, 4JHH = 1.6, H3), 1.66 (s, 3H,
4JHH = 1.6, H1). APT-
13C{1H} NMR
[(CD3)2CO, δ (ppm)]: 156.3 (C9), 156.1 (
3JCP = 1.9, C5), 153.7 (C7),
133.8 (2JPC = 11, CHoPPh3), 132.9 (
1JPC = 40, CqPPh3), 130.8 (
4JPC =
2, CHpPPh3), 129.3 (
3JPC = 9, CHmPPh3), 123.6 (C6), 120.8 (C8),
103.0 (C2), 76.7 (C4), 76.6 (C3), 62.5 (C10), 11.7 (C1).
31P NMR
[(CD3)2CO, δ (ppm)]: 51.9 [s, PPh3]. FTIR [KBr, cm
−1]: 3429 cm−1
(υO−H), 3084−3065 cm−1 (υC−H, phenyl, MeCp); 2922−2855 cm−1
(υC−H MeCp), 1440 (υCC, phenyl rings, MeCp), 1256 cm−1
(υCF3SO3 counterion), 1225 cm
−1 (υC−O). UV−vis [DMSO, λmax
(nm) (ε × 103 M−1 cm−1)]: 290 (54.0), 350 (Sh), 422 (6.8), 480 (Sh).
UV−vis [CH2Cl2, λmax (nm) (ε × 103 M−1 cm−1)]: 292 (20.8), 332
(Sh), 354 (Sh), 424 (3.6), 472 (Sh). Elemental analysis. Calcd for
C37H34F3N2O5PRuS·1/2 CH2Cl2: C, 53.0; H, 4.2; N, 3.3; S, 3.8.
Found: C, 53.0; H, 4.0; N, 3.4; S, 4.0.
X-ray Crystal Structure Determination. Three-dimensional X-
ray data for [Ru(η5-MeCp)(PPh3)(bpy)][CF3SO3] (Ru1), [Ru(η
5-
MeCp)(PPh3)(Me2bpy)][CF3SO3]·CH2Cl2 (Ru2), and [Ru(η
5-
MeCp)(PPh3)(bpy(CH2OH)2))][CF3SO3] (Ru3) were collected on
a Bruker SMART Apex CCD diffractometer at 100(2) K using a
graphite monochromator and Mo Kα radiation (λ = 0.71073 Å) by the
ϕ−ω scan method. Reflections were measured from a hemisphere of
data collected of frames each covering 0.3° in ω. A total of 68 350,
152 907, and 71 274 reflections for Ru1, Ru2, and Ru3, respectively,
were measured, all of which were corrected for Lorentz and
polarization effects and for absorption by semiempirical methods
based on symmetry-equivalent and repeated reflections. Of the total,
5 806 for Ru1, 13 003 for Ru2, and 6 383 for Ru3 independent
reflections exceeded the significance level |F|/σ(|F|) > 4.0. After data
collection, in each case a multiscan absorption correction (SADABS)42
was applied, and the structures were solved by direct methods and
refined by full matrix least-squares on F2 data using the SHELX suite
of programs.43 The non-hydrogen atoms were refined with anisotropic
thermal parameters in all cases. Hydrogen atoms were included in
calculation positions and refined in the riding mode, except for O1 and
O2 atoms in Ru3, which were located in difference Fourier map and
left to refine freely. A final difference Fourier map showed no residual
density outside, 0.548 and −0.500 e·Å−3 for Ru1 and 0.430 and
−0.522 e·Å−3 for Ru3, except for compound Ru2, which presents a
residual density outside next to the CF3SO3 ion and around solvent
molecules, which was not refined: 2.165 and −0.957 e·Å−3. Weighting
schemes w = 1/[σ2(Fo
2) + (0.036700P)2 + 2.273600P] for Ru1, w = 1/
[σ2(Fo
2) + (0.062900P)2 + 4.819400P] for Ru2, and w = 1/[σ2(Fo
2) +
(0.039300P)2 + 2.445400P] for Ru3, where P = (|Fo|
2 + 2|Fc|
2)/3, were
used in the latter stages of refinement. CCDC numbers 1820137−
1820139 contain the supplementary crystallographic data for Ru1,
Ru2, and Ru3. These data can be obtained free of charge via http://
www.ccdc.cam.ac.uk/conts/retrieving.html. Crystal data and details of
the data collection and refinement for the new compounds are
collected in Table S6.
DFT Studies. Ground geometries were obtained by density
functional theory (DFT) from optimizations using the hybrid meta-
GGA Thrular’s M06 functional,44,45 as implemented in Gaussian 09,46
with the LANL2DZ effective core potential basis set47,48 for P and Ru
and the 6-31G(d,p) basis set for all the other atoms. Frequency
analysis was subsequently performed in the gas-phase without any
symmetry constrains, confirming each optimized geometry as an
energy minimum by the absence of imaginary frequencies. Charge
decomposition analysis (CDA) was performed, at the same theory
level, using the QMforge software.49 The TD-DFT method was used
to calculate the low-lying excited states of the complexes using the
M06 functional with the SMD50 solvent model using the 6-31+G(d,p)
basis set together with the LANL2DZ effective core potential basis set
for the P and Ru atoms. The equations were solved for the lowest 50
excited states, and the simulated absorption bands were obtained by
convolution of Gaussian functions centered at the calculated excitation
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energies using the GaussSum 3.0 software.51 The Chemcraft 1.7
(http://www.chemcraftprog.com) program was used for the visual-
ization of the remaining computed results.
Electrochemical Experiments. The redox potentials for all
complexes were measured by cyclic voltammetry using an EG&G
Princeton Applied Research Model 273A potentiostat−galvanostat
monitored with a personal computer loaded with Electrochemistry
PowerSuite v2.51 software from Princeton Applied Research. Cyclic
voltammograms were obtained using 1 mM of complexes in anhydrous
acetonitrile or dichloromethane solutions containing tetrabutylammo-
nium hexafluorophosphate (0.1 or 0.2 M, respectively) as supporting
electrolyte. A three-electrode configuration electrochemical cell was
used with a platinum-disk working electrode (1.0 mm diameter)
probed by a Luggin capillary connected to a silver-wire pseudorefer-
ence electrode and a platinum wire auxiliary electrode. All measure-
ments were done at room temperature, and the solutions were
deaerated with nitrogen atmosphere before use. All the potentials
reported were measured against the ferrocene/ferrocenium redox
couple as internal standard and normally quoted relative to SCE (using
the ferrocenium/ferrocene redox couple E1/2 = 0.46 or 0.40 V versus
SCE for dichloromethane or acetonitrile, respectively). Reagent grade
solvents were dried, purified by standard procedures, and distilled
under nitrogen atmosphere before use.
Stability Studies in DMSO and DMSO/DMEM. For the stability
studies, all the complexes were dissolved in DMSO or 5% DMSO/
95% DMEM at ca. 0.5−1 × 10−4 M for Ru1−Ru3, and their electronic
spectra were recorded in the range allowed by the solvents at set time
intervals.
Biological Evaluation. Cell Lines and Culture Conditions. To
evaluate the selectivity of our compounds on other ABC transporters,
we used the NIH3T3 parental cell line and NIH3T3/ABCB1 drug-
resistant cell line transfected with human MDR1/A-G185, purchased
from American Type Culture Collection (Manassas, VA) and used as
described previously.52 HEK293 (Human embryonic kidney cell) was
used to express ABCG253 and Flp-In-293 cells to express ABCC1 and
ABCC2 genes as described previously54 transfected by electroporation
using a Neon Transfection System (ThermoFisher scientific) with
pcDNA5-FRT-ABCC2. Human A2780 (cisplatin-sensitive) and
A2780cis (cisplatin-resistant) ovarian cancer cell lines were purchased
from Sigma-Aldrich.
Cells were grown at 37 °C in 5% CO2 in Dulbecco’s modified
Eagles’s medium (DMEM high glucose) (PAA, GE Healthcare Life
Sciences, Velizy-Villacoublay, France) supplemented with 10% fetal
bovine serum (FBS, PAA, GE Healthcare Life sciences, Velizy-
Villacoublay, France), 1% penicillin/streptomycin (PAA, GE Health-
care Life Sciences, Velizy-Villacoublay, France), with selection for the
MRP1, MRP2, BCRP for HEK293, and P-gp-transfected cell line for
NIH3T3. The A2780/A2780cisR cells were cultured in RPMI 1640
medium with 10% FBS and 1% antibiotics, HEPES, and L-glutamine.
All the cells were adherent in monolayers and, upon confluence,
were washed with phosphate buffer saline (PBS) 1× and harvested by
digestion with trypsin 0.05% (v/v). Trypsin was inactivated by adding
fresh complete culture media to the culture flask. Cells were then
suspended and transferred into new, sterile culture flasks or seeded in
sterile test plates for the different assays.
All cells were manipulated under aseptic conditions in a flow
chamber.
Compound Dilution and Storage. All compounds were dissolved
in DMSO and divided in aliquots of 10 μL each. They were store at
−20 °C until use.
Compound Cytotoxicity Evaluated by MTT Assay. Cell survival
was studied by using the MTT (3-(4,5-2-yl)-2,5-ditetrazolium
bromide) colorimetric assay. Cells were plated in 96-well sterile plates
at a density to ensure exponential growth of untreated control samples
throughout the experiment, 104 cells per well with 200 μL of medium.
For 24 h, cells were allowed to settle followed by the addition of
dilution series of the test compounds. Complexes were solubilized in
DMSO/DMEM, with a maximum of 0.5% of DMSO per
concentration, in a range of 0−200 μM. After continuous exposure
to the compounds for 48 h, at 37 °C with 5% of CO2, the media were
removed, and cells were incubated with MTT solution in PBS (0.5
mg/mL) at the same conditions. After 4 h, the yellow solution was
carefully removed, and the purple formazan crystals formed inside the
cells were dissolved with DMSO through shaking. The cellular viability
was evaluated by measurement of the absorbance at 570 nm by using a
plate spectrophotometer, and this was corrected with the absorbance
measured at 690 nm.
For A2780 and A2780cisR cell lines, cells were plated in 96-well
sterile plates in complete RPMI medium at a density to ensure
exponential growth of the controls (cells with no treatment)
throughout the assay. Cells (104 cells/200 μL medium) were allowed
to settle for 24 h before the addition of dilution series of the test
compounds. Complexes were first solubilized in DMSO and then in
medium with a maximum of 1% of DMSO for the higher
concentration, in a range of 0.01−100 μM. After continuous exposure
to the compounds for 24 h, at 37 °C with 5% of CO2, the medium was
removed, and cells were incubated with MTT solution in PBS (0.5
mg/mL). After 3 h, the yellow solution was carefully removed, and the
purple formazan crystals formed inside the cells were dissolved with
DMSO through shaking. The cellular viability was evaluated by
measurement of the absorbance at 570 nm using a plate
spectrophotometer.
Flow Cytometry. Cells were seeded at a density of 105 cells/well
into 24-well culture plates. After a 24 h incubation period, they were
exposed to different concentrations of compounds and substrates for
30 min at 37 °C, 5% CO2. After treatment, cells were washed with
phosphate buffer saline (PBS) and detached from the plates with
trypsin. Then the media was neutralized with PBS, resuspended, and
transferred to cytometer tubes. The samples were kept in ice until the
analysis (for a maximum of 2 h) in a FACSCalibur cytometer (BD
Biosciences, San Jose, CA) and a BD LSR-II system.
Ru1−Ru3 Uptake Evaluation in Single Cells by Mass Cytometry.
Cells were seeded in 6-well plates for 48 h to reach a density of ∼106
cells/mL. Cells were treated for 15 min with 20 μM compounds and
then washed with PBS, trypsinized for 5 min, washed, and transferred
to microcentrifuge tubes. Cells were then centrifuged at 300g for 5
min; the supernatant was discarded, and cells were incubated with 20
μM Ru1−Ru3 for 5 min. Cells were centrifuged again, washed with
Dulbecco’s phosphate-buffered saline (DPBS), and fixed overnight in 1
mL of 4% paraformaldehyde. The next day, the supernatant was
discarded, and we added 0.25 μM iridium to label the DNA (for 45
min). Then, we carefully washed the cells with MaxPar water and
DPBS to discard traces of metals. After one last centrifugation, cells
were then injected into a mass cytometer (cyTOF II mass cytometer,
DVS Sciences Inc.). Cells were atomized and ionized in a high-
temperature inductively coupled plasma. The atomic composition of
each cell (including metal tags) was then measured by time-of-flight
mass spectrometry, generating distinct mass spectra of each cell. The
mass cytometer can measure heavy elements naturally present or
introduced into a cell, such as iodine and Ru.
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